Literature DB >> 8056398

Regional chemotherapy (with mitomycin C) and intra-operative hyperthermia for digestive cancers with peritoneal carcinomatosis.

F N Gilly1, P Y Carry, A C Sayag, A Brachet, G Panteix, B Salle, J Bienvenu, G Burgard, B Guibert, V Banssillon.   

Abstract

Intraperitoneal chemo-hyperthermia with mitomycin C was used to treat 28 patients with far advanced digestive adenocarcinoma and histologically confirmed peritoneal carcinomatosis. Surgical resection of the primary tumor was possible in 17 cases. After closure of the abdominal wall, intraperitoneal chemo-hyperthermia was performed for 90 to 120 minutes under general anesthesia and 32 degrees C hypothermia, through 3 intraperitoneal drains forming a closed circuit, using 10 mg/l of mitomycin C in 6 liters of peritoneal dialysate heated to an inflow temperature of 46-49 degrees C. No mortality occurred, and there were 2 post-operative complications, with transitory biological side effects. In 9 out of 10 patients with preoperative malignant ascites, the ascites cleared after treatment. One-year survival rate was 54.2%. These encouraging preliminary results show that intraperitoneal chemohyperthermia with mitomycin C is a safe and reliable treatment for peritoneal carcinomatosis in far advanced digestive cancers.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8056398

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  28 in total

Review 1.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer.

Authors:  Ramakrishnan Ayloor Seshadri; Olivier Glehen
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

Review 2.  Cytoreductive surgery and intraoperative intraperitoneal hyperthermic chemotherapy in patients with peritoneal carcinomatosis of colorectal origin.

Authors:  César P Ramírez Plaza; Manuel A Cobo Dols; Alberto Gómez Portilla; Agustín de la Fuente Perucho
Journal:  Clin Transl Oncol       Date:  2005-11       Impact factor: 3.405

3.  [Scoring systems for clinical staging of peritoneal carcinomatosis. A critical analysis].

Authors:  J Jähne; S Kübler
Journal:  Chirurg       Date:  2007-12       Impact factor: 0.955

4.  Prognostic factors for peritoneal carcinomatosis originating from colorectal cancer: an analysis of 921 patients from a multi-institutional database.

Authors:  Heita Ozawa; Kenjiro Kotake; Hirotoshi Kobayashi; Hirotoshi Kobayashi; Kenichi Sugihara
Journal:  Surg Today       Date:  2014-09       Impact factor: 2.549

5.  Prognoses and treatment strategies for synchronous peritoneal dissemination of colorectal carcinoma.

Authors:  Harunobu Sato; Kunihiro Toyama; Yoshikazu Koide; Shinji Ozeki; Kouhei Hatta; Kotaro Maeda
Journal:  Surg Today       Date:  2015-10-03       Impact factor: 2.549

6.  Preoperative platelet-lymphocyte ratio is an independent prognostic marker and superior to carcinoembryonic antigen in colorectal peritoneal carcinomatosis patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Authors:  Tiffany Sin Hui Bong; Grace Hwei Ching Tan; Claramae Chia; Khee Chee Soo; Melissa Ching Ching Teo
Journal:  Int J Clin Oncol       Date:  2017-01-30       Impact factor: 3.402

7.  Outcomes of surgery without HIPEC for synchronous peritoneal metastasis from colorectal cancer: data from a multi-center registry.

Authors:  Hirotoshi Kobayashi; Kenjiro Kotake; Kenichi Sugihara
Journal:  Int J Clin Oncol       Date:  2012-12-13       Impact factor: 3.402

8.  Laparoscopic cytoreductive surgery and early postoperative intraperitoneal chemotherapy for patients with colorectal cancer peritoneal carcinomatosis: initial results from a single center.

Authors:  Soo Yeun Park; Gyu-Seog Choi; Jun Seok Park; Hye Jin Kim; Jong-Pil Ryuk; Sung-Hwan Yun; Jong Gwang Kim; Byung Woog Kang
Journal:  Surg Endosc       Date:  2013-12-25       Impact factor: 4.584

9.  Efficacy of paclitaxel-based doublet regimens combining with intraperitoneal chemotherapy for advanced gastric cancer with peritoneal metastasis.

Authors:  Yu Chen; Wei-Feng Tang; Jing Lin; Yi Shi; Xiao-Jie Wang; Qiang Chen; Zeng-Qing Guo
Journal:  Int J Clin Exp Med       Date:  2015-10-15

Review 10.  Using pharmacologic data to plan clinical treatments for patients with peritoneal surface malignancy.

Authors:  Kurt Van der Speeten; Oswald Anthony Stuart; Paul H Sugarbaker
Journal:  Curr Drug Discov Technol       Date:  2009-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.